In Q4 2025 MOFF committed $250,000.00 to the ALS Investment Fund (ALS IF III)
ALS IF III is a Venture Capital entity based in the Netherlands, that is cultivating a portfolio of companies developing potential therapies for neurodegenerative diseases.
MOFF has historically philanthropically invested in the “valley of death” stage of drug development, or the early, high risk time frame, which includes animal studies, basic disease understanding projects, and early preclinical studies. At the time (2013-2024), the ALS research community needed to gain a deeper understanding of the disease, and MOFF supported this effort.
Now, according to a Guggenheim Parters report from May 2025, there are an estimated 65 potentially therapies in drug development pipelines. This represents a shift in ALS drug development from basic disease understanding, to clinical therapy development. Therefore, MOFF resources are best spent supporting clinical phase projects on their way to patients in need now.
MOFF has been aware of the ALS Investment Fund since 2017 and had the opportunity to meet with their team, Melanie Leitner (CSO) and Craig Boyce (Managing Partner) in Boston in Nov 2025. Their scientific, industry, and financial knowlege is unquestionable and their alliance with the ALS community is unfaltering.
Four companies within the ALS Investment IF III portfolio are listed below. Click on their logos to learn more.
